Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Randomized, Open-label, Multiple-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AMG 334 in Children and Adolescents With Migraine

NCT03499119 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03499119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03499119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Randomized, Open-label, Multiple-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AMG 334 in Children and Adolescents With Migraine
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
May 4, 2018
Completion date
November 23, 2021
Enrollment
53 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

migraine